Posted innews
Evolocumab 预防高风险患者首次发生主要心血管事件
在 VESALIUS-CV 研究中，与安慰剂相比，evolocumab 将无既往心肌梗死或卒中的动脉粥样硬化或糖尿病患者的首次主要不良心血管事件减少了约 25%（HR 0.75），绝对风险降低幅度较小，随访 4.6 年未发现新的安全性信号。
Posted inCardiology Diabetes & Endocrinology news
Evolocumab Prevents First Major Cardiovascular Events in High‑Risk Patients without Prior MI or Stroke
In VESALIUS-CV, evolocumab reduced first major adverse cardiovascular events by ~25% (HR 0.75) versus placebo in patients with atherosclerosis or diabetes without prior myocardial infarction or stroke, with modest absolute risk reductions and no new safety signals over 4.6 years.
Posted inCardiology news
PCSK9 Inhibition Prevents First Major Cardiovascular Events: VESALIUS‑CV trial
In the VESALIUS‑CV trial, evolocumab reduced first major adverse cardiovascular events by 25% (3‑point MACE) and 19% (4‑point MACE) versus placebo over 4.6 years in patients with atherosclerosis or diabetes and no prior MI or stroke.
Posted inCardiology news Specialties
Evolocumab and Saphenous Vein Graft Patency Post-CABG: Insights from the NEWTON-CABG Trial
The NEWTON-CABG CardioLink-5 trial found that intensive LDL-C lowering with evolocumab did not improve saphenous vein graft patency 24 months after coronary artery bypass surgery despite significant LDL-C reductions.
Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial
The FOURIER trial reveals intensive LDL-C lowering with evolocumab substantially reduces cardiovascular events in type 1 diabetes patients with ASCVD, highlighting significant clinical benefit and urging further dedicated research.
Posted inCardiology Clinical Updates news Specialties
Evolocumab for Intensive LDL Cholesterol Reduction in Autoimmune and Inflammatory Disease Patients: Insights from the FOURIER Trial
Evolocumab significantly lowers LDL cholesterol and substantially reduces cardiovascular events in patients with autoimmune/inflammatory diseases alongside statin therapy, according to the FOURIER trial analysis.